MetaCap

Adagene (ADAG) vs BGM Group (BGM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adagene (ADAG) has outperformed BGM Group (BGM) over the past year, losing 2.2% versus a loss of 96.7%. Over five years, ADAG leads with a -79.7% price change compared with -98.3% for BGM. Adagene is the larger company by market cap ($118.2 million vs $108.6 million), about 1.1 times the size.

BGM Group converts more of its revenue into profit, with a net margin of -52.6% versus -229.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG+11.67%BGM-96.73%
+179%+34%-110%
Nov 21, 20251 yearNov 19, 2026
ADAG-81.97%BGM-98.38%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus BGM key metrics
MetricADAGBGM
Share price$1.76$8.13
Market cap$118.17M$108.57M
1-day change-12.44%0.00%
YTD return-6.88%-92.77%
1-year return-2.22%-96.73%
5-year return-79.75%-98.31%
EPS (TTM)$-0.37$-4.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M$37.92M
Revenue growth (YoY)+7332.76%+51.09%
Net income (latest FY)$-17.61M$-19.94M
Gross margin—16.64%
Operating margin-279.48%-33.18%
Net margin-229.56%-52.59%
52-week high$4.85$263.70
52-week low$1.27$0.00
Distance from 52-week high-63.71%-96.92%
Analyst consensusnone—
Avg. price target upside+463.07%—
Average volume348.81K6.18K
Shares outstanding67.14M12.69M
Employees128—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADAG has outperformed BGM by 94.5 percentage points over the past year.
  • BGM Group is more profitable, keeping -52.6 cents of every revenue dollar as net income versus -229.6 cents for Adagene.
  • Adagene grew revenue faster in its latest fiscal year (+7332.76% vs +51.09%).

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About BGM Group

BGM stock →

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.

Health Care · Biotechnology: Pharmaceutical Preparations

ADAG vs BGM FAQ

Which is bigger, Adagene or BGM Group?

Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $108.57M for BGM Group (BGM).

Which stock has performed better over the past year, ADAG or BGM?

ADAG returned -2.22% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and BGM Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons